Breaking Finance News

Goldman Sachs Group Inc. disclosed Bayer (ETR:BAYN), raising its target price to 129.00EUR earlier today

Reporting a possible upside of 0.41%, Goldman Sachs Group Inc. upped the target stock price of Bayer (ETR:BAYN) to 129EUR.

On 8/29/2016, Citigroup Corp. reported on Bayer(ETR:BAYN) bumped the target price from 0.00EUR to 120.00EUR. At the time, this suggested an upside of 0.24%.

Showing a price of 91.44EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. The last stock price is up 1.82% relative to the 200-day average, compared to the S&P 500 which has decreased -0.01% over the date range. BAYN has logged a 50-day average of 0.04EUR and 200-day average of 0.03EUR. Volume of trade was was down over the average, with 0 shares of BAYN changing hands under the typical 211 shares.

Recent Performance Graphic:

Bayer (ETR:BAYN)

Bayer has a one-year low of 0.03EUR and a 52 week high of 0.04EUR. Bayer’s market cap is presently 0.0 EUR.

Brief Synopsis About Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.